TERPENOLOL: A NOVEL NANOMICELLAR, HYDROPHILIC CBD‑DERIVED COMPOUND FOR PHARMACEUTICAL, NUTRACEUTICAL, COSMECEUTICAL, AND FUNCTIONAL FOOD APPLICATIONS

Terpenolol is a newly developed hydrophilic derivative of cannabidiol (CBD) designed to overcome the solubility, stability, and pharmacokinetic limitations of conventional lipophilic CBD formulations. This study presents its physicochemical profile, 30-day stability, and preliminary pharmacokinetic behaviour in humans. Terpenolol forms a stable aqueous nanomicellar dispersion with neutral pH (7.0 ± 0.1), consistent viscosity, and minimal variation in tintometric and colloidal parameters over the observation period. In a single-dose, two-period crossover study involving five healthy volunteers, sublingual administration of Terpenolol resulted in markedly higher plasma CBD concentrations at 30 minutes compared with an oil-based reference formulation. Observational data from more than 200 individuals using Terpenolol-based preparations across oral, nasal, cutaneous, and transdermal routes indicate good tolerability and reported improvements in anxiety, panic symptoms, insomnia, psychotic- spectrum disturbances, and musculoskeletal or joint pain. The compound’s complete solubility in aqueous media, combined with its neutral taste and odourless profile, also supports its incorporation into functional beverages, as demonstrated by a prototype mineral water formulation containing 50 mg of CBD in 500 ml. Overall, Terpenolol demonstrates physicochemical stability, improved early systemic exposure to CBD, and broad compatibility with formulations. Controlled studies are planned to further define its pharmacological relevance and potential application domains.

• Alhadid, A., Luca, S. V., Nasrallah, S., & Minceva, M. (2023). Experimental investigation and thermodynamic modelling of cannabidiol solubility in plant oils and hydrophobic eutectic systems. Journal of Molecular Liquids, 372: 121172. https://doi.org/10.1016/j.molliq.2022.121172 (doi.org in Bing)
• Bhuller, R., Schlage, W. K., & Hoeng, J. (2024). Review of the current ongoing clinical trials exploring the possible anti-anxiety effects of cannabidiol. Journal of Cannabis Research, 6: 40. https://doi.org/10.1186/s42238-024- 00250-y (doi.org in Bing)
• Cásedas, G., de Yarza Sancho, M., & López, V. (2024). Cannabidiol (CBD): A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals, 17(11): 1438. https://doi.org/10.3390/ph17111438
• Coelho, C. F., Vieira, R. P., Araújo Junior, O. S., Lopes Martins, P. S., dos Santos, L. G., Dias, L. D., Lopes Martins, R. A. B. (2024). The impact of cannabidiol treatment on anxiety disorders: A systematic review of randomized controlled clinical trials. Life, 14(11): 1373. https://doi.org/10.3390/life14111373 (doi.org in Bing) 
• Fabris, D., Lisboa, J. R., Guimarães, F. S., & Gomes, F. V. (2024). Cannabidiol as an antipsychotic drug. International Review of Neurobiology, 177:           295–317. https://doi.org/10.1016/S0074-7742(24)00065-5 (doi.org in Bing)
• Lavender, I., Garden, G., Grunstein, R. R., Yee, B. J., & Hoyos, C. M. (2024). Using cannabis and CBD to sleep: An updated review. Current Psychiatry Reports, 26: 712–727. https://doi.org/10.1007/s11920-024-01564-7
• Mejuto, J. C., & Poša, M. (2024). Design and Applications of Self-Assembly Aggregates: From Micelles to Nanoemulsions. IntechOpen. https://doi.org/10.5772/intechopen
• Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., & Bifulco, M. (2017). Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacology & Therapeutics, 175: 133–150. https://doi.org/10.1016/j.pharmthera.2017.02.041
• Scrimali, T. (2020). NegEnt: A cannabidiol-based, herbal medicine. International Journal of Herbal Medicine, 8(5): 143–151.
• Scrimali, T. (2022). NegEnt: Cannabidiolo Liposomiale in Medicina Umana e Veterinaria. Enna: ALETEIA Publisher. Scrimali, T. (2023). Safety and Tolerability of NegEnt, a New Botanical Product Based on Liposomal Cannabidiol: A Case Series Report. Journal of Nutraceuticals and Food Science, 8(1): 08.
• Scrimali, T. (2024). From CBT to Complex Therapy: A Novel Approach to the Treatment of Mental Disorders.
• Preprints.org. https://doi.org/10.20944/preprints202403.0594.v
• Scrimali, T. (2025). NegEnt: Cura Naturale Complessa per la Salute Umana e dei Pet. Enna: ALETEIA Publisher.
• Schwarzenberg, A., Carpenter, H., Wright, C., Bayazeid, O., & Brokl, M. (2022). Characterizing the degradation of cannabidiol in an e-liquid formulation. Scientific Reports, 12 : 19645. https://doi.org/10.1038/s41598-022- 23910-6
• Su, Y. T., & Zhang, J. (2024). Solubility enhancement and antioxidation maintenance of cannabidiol encapsulated in the P407-RUB nano-micelle system. Current Drug Delivery, 21(2):      271–282. https://doi.org/10.2174/1567201820666230330090025
• Wang, X., Zhang, H., Liu, Y., Xu, Y., Yang, B., Li, H., & Chen, L. (2023). An overview on synthetic and biological activities of cannabidiol (CBD) and its derivatives. Bio-organic Chemistry, 140: 106810. https://doi.org/10.1016/j.bioorg.2023.106810